Publications associées à TAT-based Formal Representation of Medical Guidelines : Imatinib Case-study

Publications associées (12)

Direct Model-checking of SysML Models

Model-checking intends to verify whether a property is satisfied by a model, or not. Model-checking of high-level models, e.g. SysML models, usually first requires a model transformation to a low level formal specification. The present papers proposes a ne ...

SCITEPRESS2021

Scaling Functional Synthesis and Repair

Emmanouil Koukoutos

Program synthesis was first proposed a few decades ago, but in the last decade it has gained increased momentum in the research community. The increasing complexity of software has dictated the urgent need for improved supporting tools that verify the soft ...

EPFL2019

Allosteric kinase inhibitors

Oliver Hantschel

Background. Inhibition of the kinase activity of the BCR-ABL1 oncoprotein by an allosteric mechanism of action facilitates alternative treatment options for chronic myeloid leukemia (CML) patients who cannot be adequately treated with conventional catalyti ...

Springer Nature2017

Functional malignant cell heterogeneity in pancreatic neuroendocrine tumors revealed by targeting of PDGF-DD

Iacovos Michael

Intratumoral heterogeneity is an inherent feature of most human cancers and has profound implications for cancer therapy. As a result, there is an emergent need to explore previously unmapped mechanisms regulating distinct subpopulations of tumor cells and ...

National Academy of Sciences2016

Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition

Hubert van den Bergh, Patrycja Nowak-Sliwinska

The angiogenesis inhibitor sunitinib is a tyrosine kinase inhibitor that acts mainly on the VEGF and PDGF pathways. We have previously shown that sunitinib is sequestered in the lysosomes of exposed tumor and endothelial cells. This phenomenon is part of t ...

Nature Publishing Group2015

Representation of Medical Guidelines with a Computer Interpretable Model

Giovanni De Micheli, Alena Simalatsar, Wenqi You Dubout

Nowadays medical software is tightly coupled with medical devices that perform patient state monitoring and lately even some basic treatment procedures. Medical guidelines (GLs) can be seen as specification of a medical system which requires their computer ...

World Scientific Publ Co Pte Ltd2014

Mechanisms of resistance to BCR-ABL and other kinase inhibitors

Orest Kuzyk, Oliver Hantschel, Allan Joaquim Lamontanara, Emel Basak Gencer Akçok

In this article, we are reviewing the molecular mechanisms that lead to kinase inhibitor resistance. As the oncogenic BCR-ABL kinase is the target of the first approved small-molecule kinase inhibitor imatinib, we will first focus on the structural and mec ...

Elsevier Science Bv2013

-Overify: Optimizing Programs for Fast Verification

George Candea, Volodymyr Kuznetsov, Jonas Benedict Wagner

Developers rely on automated testing and verification tools to gain confidence in their software. The input to such tools is often generated by compilers that have been designed to generate code that runs fast, not code that can be verified easily and quic ...

USENIX Association2013

Parameterized SVM for Personalized Drug Concentration Prediction

Giovanni De Micheli, Alena Simalatsar, Wenqi You Dubout

This paper proposes a parameterized Support Vector Machine (ParaSVM) approach for modeling the Drug Concentration to Time (DCT) curves. It combines the merits of Support Vector Machine (SVM) algorithm that considers various patient features and an analytic ...

2013

Structure, regulation, signaling, and targeting of abl kinases in cancer

Oliver Hantschel

Abl kinases are prototypic cytoplasmic tyrosine kinases and are involved in a variety of chromosomal aberrations in different cancers. This causes the expression of Abl fusion proteins, such as Bcr-Abl, that are constitutively activated and drivers of tumo ...

2012

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions

Oliver Hantschel

Nilotinib is a second generation ABL tyrosine kinase inhibitor (TKI) that exerts major anti-leukemic effects in newly diagnosed patients with chronic myeloid leukemia (CML) as well as in most patients with imatinib-resistant CML. In freshly diagnosed patie ...

2012

Robust safety of timed automata

Timed automata are governed by an idealized semantics that assumes a perfectly precise behavior of the clocks. The traditional semantics is not robust because the slightest perturbation in the timing of actions may lead to completely different behaviors of ...

Springer US2008